Orthofix International

Orthofix Medical, Inc. engages in the provision of medical devices. It operates through the following business segments: Global Spine and Global Extremities. The Global Spine reporting segment offers three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics. The Bone Growth Therapies product category manufactures, distributes, and provides support services of bone growth stimulator devices that enhance bone fusion. The Spinal Implants product category designs, develops, and markets a broad portfolio of motion preservation and fixation implant products used in surgical procedures of the spine. The Biologics product category provides a portfolio of regenerative products and tissue forms that allow physicians to treat a variety of spinal and orthopedic conditions. The Global Extremities reporting segment offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. The company was founded on October 19, 1987 and is headquartered in Lewisville, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Orthofix and SeaSpine post mixed Q4 results, eye synergies and growth

SeaSpine and Orthofix reported mixed Q4 performances but demonstrated overall revenue growth for the full year, with positive revenue guidance for 2023.
The merger synergies and product demand strengths are key highlights, while challenges in profitability and regulatory hurdles in Europe require attention.
Opportunities lie in integration efforts, cost efficiencies, and exploring new markets, indicating a strategic growth trajectory for the combined entity.
The upcoming Analyst Teach-In event and focus on operational planning underscore the commitment to transparency and strategic alignment post-merger.

Orthofix reports robust Q1 earnings, raises full-year revenue guidance

Orthofix International's Q1 2023 earnings call highlighted strong financial performance, strategic initiatives, and raised revenue guidance, underscoring growth prospects.
The company's focus on operational efficiency, product categories, and profitability signals a resilient business strategy amidst market challenges and competitive landscape.
With a robust financial foundation, Orthofix is well-positioned to navigate challenges, capitalize on growth opportunities, and drive sustainable value creation for shareholders.

Orthofix International reports robust Q2 earnings and growth outlook

Orthofix International delivered a strong Q2 performance, with notable revenue growth and positive outlook for 2023.
Efforts to integrate merged businesses are yielding results, with a focus on revenue enhancement and operational streamlining.
Challenges such as cash flow and supply chain disruptions are being addressed through strategic investments and operational improvements.
The company's focus on growth, efficiency, and strategic partnerships positions it well for future success and value creation.

Orthofix reports robust Q3 revenue growth, eyes profitability and stability

Orthofix International demonstrated strong revenue growth and market performance in Q3 2023, driven by successful product lines and strategic initiatives.
While facing challenges such as cash flow outflows and margin adjustments, the company remains focused on profitability and financial stability.
Opportunities lie in sustaining positive momentum, achieving cash flow positivity in 2024, and leveraging growth prospects through product innovation and market expansion.

Orthofix reports robust Q4 earnings, eyes growth in key segments

Orthofix International's Q4 2023 earnings call highlighted strong financial performance, strategic initiatives, and growth in key segments.
The company's focus on market share, distributor relationships, and portfolio enhancements positions it well for future success.
Despite challenges in a competitive landscape, Orthofix remains optimistic about growth opportunities and aims for continued innovation and collaboration.

Orthofix International reports robust Q1 earnings and raises 2024 guidance

Orthofix International (OFIX) delivered a strong Q1 2024 performance, focusing on growth, innovation, and operational efficiency. The company showcased revenue growth, margin expansion, and strategic priorities for the year. Challenges include sustaining growth in competitive markets and optimizing operational aspects, while opportunities lie in leveraging technology and talent for further growth.

Orthofix International reports strong Q2 performance and outlines growth strategies

Orthofix International's Q2 performance reflects solid revenue growth and margin expansion, supported by new product releases and operational efficiency.
While facing challenges in cash flow optimization, the company's strategic focus on innovation and synergies positions it well for future growth.
Opportunities in technology investment, cross-selling, and distribution enhancements offer avenues for Orthofix International to drive sustained growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Integer Holdings

Merit Medical Systems

Backed by robust long-term prospects, investors can add three lucrative MedTech stocks, MMSI, ITGR and OFIX, to their watchlist.

3 Promising MedTech Stocks to Snap Up in Second-Half 2021

OrthoPediatrics

SeaSpine Holdings

Stryker

Zimmer Biomet Hlds

OrthoPediatrics (KIDS), Orthofix (OFIX), Zimmer Biomet (ZBH), Stryker (SYK) and SeaSpine (SPNE) are expected to hold ground despite a challenging business climate.

5 Stocks to Deflect Delta Variant Curveball From Orthopedic Space

LEWISVILLE, Texas--(BUSINESS WIRE)--Former Roche Diagnostics CFO Wayne Burris Appointed to the Orthofix Board of Directors

Orthofix Announces Appointment of Wayne Burris to Board of Directors

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix adds Opus Mg Set - a magnesium based bone void filler for orthopedic procedures to the company's Biologic portfolio.

Orthofix Announces Full Market Launch of Opus Mg Set – a Magnesium-based Settable Bone Void Filler for Orthopedic Procedures

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will participate in a fireside chat during the upcoming Sidoti Virtual Investor Conference on Thursday, September 23, 2021 at 2:30 p.m. ET. The conference will be held in a virtual format, and one-on-one meetings will be held before and immediatel

Orthofix Announces Participation in Upcoming Sidoti Virtual Investor Conference

Orthofix's (OFIX) Fitbone system is the only intramedullary limb lengthening solution to get FDA clearance for pediatric and adult use.

Orthofix (OFIX) Fitbone Used in 1st US Pediatric Patient Implant

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix announces the first U.S. pediatric patient implant with the Fitbone™ system for limb lengthening of the femur and tibia bones.

Orthofix Announces First US Pediatric Implant of the Fitbone Limb-Lengthening System

Orthofix Medical's (OFIX) CEO Jon Serbousek on Q2 2021 Results - Earnings Call Transcript

Orthofix Medical Inc (NASDAQ: OFIX) reported Q2 adjusted EPS $0.32, compared to an adjusted net loss of $(0.59) a year ago, beating the consensus of $0.11. Sales increased 66% to $121.4 million.

Orthofix Stock Ticks Up On Street-Beating Q2 Earnings; Raises FY21 Outlook

Orthofix (OFIX) delivered earnings and revenue surprises of 100.00% and 11.01%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) Tops Q2 Earnings and Revenue Estimates

Shares of Orthofix Medical (NASDAQ:OFIX) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share increased 154.24% over the past year to $0.32, which beat the estimate of $0.11.

Orthofix Medical: Q2 Earnings Insights

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended June 30, 2021. Net sales were $121 million, earnings per share (“EPS”) was $0.12, and adjusted EPS was $0.32. “We are proud of our second quarter performance, in which we delivered accelerated topline growth sequentially and over pre-COVID levels,” said Orthofix President and Chief Executive Officer Jon Serbousek. “We continue to see the positive impacts of our stra

Orthofix Reports Second Quarter 2021 Results

LEWISVILLE, Texas--(BUSINESS WIRE)--First implant completed in Orthofix study evaluating the M6-C artificial cervical disc for treating degenerative disc disease at two vertebral levels.

Orthofix Announces First Patient Implant in the M6-C Artificial Cervical Disc Two-Level IDE Study

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Orthofix (OFIX) Earnings Expected to Grow: Should You Buy?

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that it plans to release financial results for the second quarter 2021 before market open on Friday, August 6, 2021. Jon Serbousek, President and Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company's results at 8:30 a.m. ET the same day. Interested parties may access

Orthofix Schedules Second Quarter Earnings Release and Conference Call for August 6, 2021

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix launches the fiberFUSE™ Strip, a preformed bone-graft optimized for posterior cervical, posterior lumbar and degenerative spinal procedures.

Orthofix Announces US Launch and First Patient Implants with New fiberFUSE Strip – An Advanced Fiber Bone-Graft Solution Containing Cancellous Bone

Orthofix's (OFIX) SpinalStim bone growth device demonstrates impressive fusion rates for patients recovering from lumbar fusion surgery.

Orthofix's (OFIX) SpinalStim Demonstrates Improved Fusion Rates

LEWISVILLE, Texas--(BUSINESS WIRE)--Publication of data evaluating lumbar fusion rates in patients treated adjunctively with the SpinalStim™ device show a 92.7-percent fusion rate.

Publication of Data Shows High Fusion Rate in Patients Treated with PEMF Therapy Using the Orthofix SpinalStim Device

Orthofix (OFIX) launches FORZA Ti PLIF Spacer System to improve posterior lumbar interbody fusion procedures in the United States.

Orthofix (OFIX) Launches FORZA Ti PLIF Spacer System in the US

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix announces the first patient implant of 3D-printed FORZA Ti PLIF Spacer System featuring endplates designed to help facilitate bone ingrowth.

Orthofix Announces U.S. Launch and First Patient Implant of 3D-Printed FORZA Titanium PLIF Spacer System with Nanovate Technology

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will participate in a fireside chat during the upcoming JMP Securities Life Sciences Conference on Wednesday, June 16, 2021 at 11:00 a.m. ET. The conference will be held in a virtual format, and one-on-one meetings will be held before and immediat

Orthofix Announces Participation in Upcoming JMP Securities Life Sciences Conference

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will participate in a fireside chat during the upcoming Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 4:30 p.m. ET. The conference will be held in a virtual format, and one-on-one meetings will be held before and immediately following the fireside chat. A live audio webcast will be available

Orthofix Announces Participation in Upcoming Jefferies Virtual Healthcare Conference

Orthofix's (OFIX) latest innovation is expected to drive organic growth in its Global Orthopedics business.

Orthofix (OFIX) Launches OSCAR PRO System in the US & Europe

LEWISVILLE, Texas--(BUSINESS WIRE)--Launch of the OSCAR PRO for removal of bone cement in revision arthroplasty procedures or removal of bone to implant bond in cementless procedures.

Orthofix Announces US and European Full Market Launch of OSCAR PRO System for Removal of Cement During Complex Joint Revision Surgeries

LEWISVILLE, Texas--(BUSINESS WIRE)--Data for patients with the M6-C disc show retention of significant benefits in disability and neck, shoulder/arm pain scores at three and four years.

News for Orthofix International Stock (OFIX)